Assessing Whether Bio-Rad Laboratories (BIO) Looks Undervalued After Recent Share Price Softness

Assessing Bio-Rad Laboratories after recent performance Bio-Rad Laboratories (BIO) has attracted attention after a mixed stretch of returns, with the stock roughly flat over the past year but showing ...
Nasdaq

Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down

Bio-Rad Laboratories, Inc. BIO posted fourth-quarter 2025 adjusted earnings per share (EPS) of $2.51, which missed the Zacks Consensus Estimate by 2.3%. The bottom line decreased 13.4% from the ...
Nasdaq

Here's Why You Should Hold Bio-Rad Stock in Your Portfolio Now

Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, given the demand for its quality control and immunology products in Clinical Diagnostics. In addition, growth across ...
Barron's

Bio-Rad Laboratories Inc. Cl B

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
Seeking Alpha

Bio-Rad outlines 2026 margin expansion and 0.5%-1.5% revenue growth guidance amid operational improvements

Feb. 12, 2026 7:35 PM ETBio-Rad Laboratories, Inc. (BIO) Stock, BIO.B StockAI-Generated Earnings Calls Insights ...